Spots Global Cancer Trial Database for Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Official Title: Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)
Study ID: NCT00744081
Conditions
Study Description
Brief Summary: The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Frankfurt, Medical Dept. II, Frankfurt, , Germany
Contact Details
Name: Lothar Bergmann, MD, PhD
Affiliation: University Hospital of Frankfurt, Medical Dept. II
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
